Commitments and Contingencies - Additional Information (Details) - USD ($)
|
1 Months Ended |
9 Months Ended |
12 Months Ended |
Feb. 28, 2021 |
Dec. 31, 2020 |
Jan. 31, 2019 |
Nov. 30, 2018 |
Sep. 30, 2022 |
Dec. 31, 2021 |
| Regeneron |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Term of agreement |
5 years
|
|
|
|
|
|
| THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Term of agreement |
|
20 years
|
|
|
|
|
| Combined milestone payment maximum |
|
$ 112,000,000
|
|
|
|
|
| UTSW | Amended Patent And Technology License Agreement |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Payments due related to milestones |
|
|
|
|
$ 0
|
$ 0
|
| UTSW | Patent And Technology License Agreement |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Term of agreement |
|
20 years
|
|
|
|
|
| Combined milestone payment maximum |
|
$ 112,000,000
|
|
|
|
|
| Payments due related to milestones |
|
|
|
|
$ 0
|
$ 0
|
| Percentage of royalty description |
|
|
|
|
There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).
|
There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).
|
| Claim expiration term |
|
10 years
|
|
|
|
|
| Minimum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Milestone payment |
|
$ 1,000,000
|
|
|
|
|
| Minimum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales up to $1,000,000,000 |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Rate of royalties on net sales |
|
|
|
2.00%
|
|
|
| Minimum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales above $1,000,000,000 |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Rate of royalties on net sales |
|
2.50%
|
|
|
|
|
| Minimum | UTSW | Patent And Technology License Agreement |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Milestone payment |
|
$ 1,000,000
|
|
|
|
|
| Minimum | UTSW | Patent And Technology License Agreement | Net sales up to $1,000,000,000 |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Rate of royalties on net sales |
|
2.00%
|
|
|
|
|
| Minimum | UTSW | Patent And Technology License Agreement | Net sales above $1,000,000,000 |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Rate of royalties on net sales |
|
2.50%
|
|
|
|
|
| Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Milestone payment |
|
$ 50,000,000
|
|
|
|
|
| Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales up to $1,000,000,000 |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Rate of royalties on net sales |
|
|
|
4.00%
|
|
|
| Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales above $1,000,000,000 |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Rate of royalties on net sales |
|
5.00%
|
|
|
|
|
| Maximum | UTSW | Patent And Technology License Agreement |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Milestone payment |
|
$ 50,000,000
|
|
|
|
|
| Maximum | UTSW | Patent And Technology License Agreement | Net sales up to $1,000,000,000 |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Rate of royalties on net sales |
|
4.00%
|
|
|
|
|
| Maximum | UTSW | Patent And Technology License Agreement | Net sales above $1,000,000,000 |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Rate of royalties on net sales |
|
5.00%
|
|
|
|
|
| Maximum | University Of Texas European | G M C I |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Research program expenditures |
|
|
|
$ 46,000
|
|
|
| Maximum | University Of Texas European | M A I A Biotechnology Inc |
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
| Research program expenditures |
|
|
$ 46,000
|
|
|
|